Rebound effect, discontinuation, and withdrawal syndromes associated with drugs used in psychiatric and neurological disorders
- PMID: 39710834
- DOI: 10.1007/s43440-024-00689-z
Rebound effect, discontinuation, and withdrawal syndromes associated with drugs used in psychiatric and neurological disorders
Abstract
Sudden cessation of the drug can cause withdrawal syndrome, discontinuation syndrome, or rebound effect. The common feature of these phenomena is a quick onset, usually limited duration depending on the drug's half-life and remission after restarting the therapy. They are characterized by varying clusters of somatic, autonomic, and psychiatric symptoms. Originally withdrawal syndrome was described for drugs with addictive properties such as barbiturates or benzodiazepines. On the other hand sudden abrupt of antidepressants or antipsychotics may cause discontinuation symptoms including movement or sensory disturbances, sleep disturbances, and hyperarousal but generally of less severity comparing to withdrawal syndrome. The aforementioned syndromes are physiologically based on the predominance of cellular counter-regulations as an effect of the sudden abrupt of a regularly taken medication. Classically the pathogenesis of withdrawal syndrome, based on physical dependence, results in life-threatening, long-lasting manifestations such as, seizures and delirium, different from the treated disease. In turn, these symptoms are not typical for discontinuation syndrome which is not considered as serious and usually spontaneously resolving. In turn, the rebound effect is clinically characterized by the relapse of the disease symptoms that are controlled by medication, but of greater severity than those before treatment.In the current review, we describe withdrawal and discontinuation syndromes associated with selected drugs used in psychiatry and neurology, risk factors, and recommendations for diminishing syndrome occurrence. Knowledge of their pathogenesis and symptoms resulting from drug discontinuation may be helpful in syndrome management and expectantly reduces the risk of diagnostic and therapeutic errors.
Keywords: discontinuation syndrome; neurological drugs; psychiatric drugs; rebound symptoms; withdrawal syndrome.
© 2024. The Author(s) under exclusive licence to Maj Institute of Pharmacology Polish Academy of Sciences.
Conflict of interest statement
Declarations. Competing interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations.CNS Drugs. 2013 Jul;27(7):545-72. doi: 10.1007/s40263-013-0079-5. CNS Drugs. 2013. PMID: 23821039 Review.
-
Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications.Psychother Psychosom. 2020;89(5):283-306. doi: 10.1159/000506868. Epub 2020 Apr 7. Psychother Psychosom. 2020. PMID: 32259826 Review.
-
Atypical antipsychotics: CATIE study, drug-induced movement disorder and resulting iatrogenic psychiatric-like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes.Psychother Psychosom. 2008;77(2):69-77. doi: 10.1159/000112883. Epub 2008 Jan 25. Psychother Psychosom. 2008. PMID: 18230939 No abstract available.
-
Rebound phenomena: results of a 10 years' (1970--1980) literature review.Int Pharmacopsychiatry. 1982;17(4):194-237. doi: 10.1159/000468579. Int Pharmacopsychiatry. 1982. PMID: 6136487
-
[Stopping antidepressants: withdrawal symptoms and rebound effects : Review and practical recommendations].Nervenarzt. 2022 Jan;93(1):93-101. doi: 10.1007/s00115-021-01243-5. Epub 2022 Jan 3. Nervenarzt. 2022. PMID: 34978577 German.
Cited by
-
Succinic acid enhances sedative activity of diazepam through GABAergic receptor modulation: Evidence from behavioral approach and computational insights.Naunyn Schmiedebergs Arch Pharmacol. 2025 Aug 21. doi: 10.1007/s00210-025-04538-5. Online ahead of print. Naunyn Schmiedebergs Arch Pharmacol. 2025. PMID: 40839005
-
Fluctuating course of attention-deficit/hyperactivity disorder across development: Multifactorial influences.World J Psychiatry. 2025 Aug 19;15(8):107780. doi: 10.5498/wjp.v15.i8.107780. eCollection 2025 Aug 19. World J Psychiatry. 2025. PMID: 40837790 Free PMC article. Review.
References
-
- Authier N, Balayssac D, Sautereau M, Zangarelli A, Courty P, Somogyi AA, Vennat B, Llorca PM, Eschalier A. Benzodiazepine dependence: focus on withdrawal syndrome. Ann Pharm Fr. 2009;67(6):408–13. https://doi.org/10.1016/j.pharma.2009.07.001 . Epub 2009 Sep 18. PMID: 19900604. - DOI - PubMed
-
- Klein RL, Harris RA. Regulation of GABAA receptor structure and function by chronic drug treatments in vivo and with stably transfected cells. Jpn J Pharmacol. 1996;70(1):1–15. https://doi.org/10.1254/jjp.70.1 . PMID: 8822084.
-
- Simpson EH, Kellendonk C. Insights About Striatal Circuit Function and Schizophrenia From a Mouse Model of Dopamine D2 Receptor Upregulation. Biol Psychiatry. 2017;81(1):21–30. https://doi.org/10.1016/j.biopsych.2016.07.004 . Epub 2016 Jul 14. PMID: 27720388; PMCID: PMC5121031. - DOI - PubMed
-
- Tsuda M, Shimizu N, Suzuki T. Contribution of glutamate receptors to benzodiazepine withdrawal signs. Jpn J Pharmacol. 1999;81(1):1–6. https://doi.org/10.1254/jjp.81.1 . PMID: 10580363.
-
- Spies LL, Verhoog NJD, Louw A. Acquired Glucocorticoid Resistance Due to Homologous Glucocorticoid Receptor Downregulation: A Modern Look at an Age-Old Problem. Cells. 2021;10(10):2529. https://doi.org/10.3390/cells10102529 . PMID: 34685511; PMCID: PMC8533966. - DOI - PubMed - PMC
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical